Anonymous ID: 29e3ee April 29, 2020, 1:09 p.m. No.8963981   🗄️.is 🔗kun

Wow.

 

Sequential CQ / HCQ Research Papers and Reports

January to April 20, 2020

Executive Summary Interpretation of the Data In This Report

The HCQ-AZ combination, when started immediately after diagnosis, appears to be a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagious infectivity in most cases.

Anonymous ID: 29e3ee April 29, 2020, 1:12 p.m. No.8964027   🗄️.is 🔗kun   >>4039

>>8963980

Some tools might be unavailable due to heavy traffic in this file.

Try again

Learn more

Dismiss

 

kek

 

Opinion

Historical controls are used in many previous studies in medicine. In this respect, the safety of Hydroxychloroquine is well documented. When the safe use of this drug is projected against its apparent effect of decreasing the progression of early cases to ventilator use, it is difficult to understand the reluctance of the authorities in charge of U.S. pandemic management to recommend its use in early COVID-19 cases. The effects of the chloroquines were first outlined 15 years ago by the CDC’s own Special Pathogens Unit.

Anonymous ID: 29e3ee April 29, 2020, 1:13 p.m. No.8964039   🗄️.is 🔗kun

>>8964027

Why are shills trying to kill the messengers, again? Sauce is all over document.

 

24 March 2020

Pagliano P, Piazza O, De Caro F, Ascione T, Filippelli A. Is Hydroxychloroquine a possible post-exposure prophylaxis drug to limit the transmission to health care workers exposed to COVID19? Clin Infect Dis. 2020 Mar 24. https://www.ncbi.nlm.nih.gov/pubmed/32211764

PMID: 32211764 DOI: 10.1093/cid/ciaa320

Chloroquine and Hydroxychloroquine are able to inhibit replication at early stages of viral

infection. No similar effect on early phases of Coronavirus infection has been reported for other drugs proposed for SARS-CoV-2 treatment, which are able to interfere only after cell infection.

We believe that hydroxychloroquine can be effective in preventing respiratory tract invasion in HCW and that hydroxychloroquine administration as prophylactic agent could be particularly useful for HCW attending to high risk procedures on respiratory tract in COVID-19 patients.

 

Hydroxychloroquine effectiveness profile, its ability to inhibit lung viral replication for a 10-day period after only a 5- day cycle of therapy, and the large amounts of knowledge in term of safety deriving from its use for malaria prophylaxis and rheumatologic diseases permit to recommend its pre-exposure or post-exposure use for those performing procedures at high risk of viral diffusion in patients with COVID-19 pneumonia.